

# Riccardo Ponzzone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6617142/publications.pdf>

Version: 2024-02-01

102  
papers

3,573  
citations

125106

35  
h-index

162838

57  
g-index

104  
all docs

104  
docs citations

104  
times ranked

4649  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Value of Repeated Breast Surgery as a Quality Indicator in Breast Cancer Care. <i>Annals of Surgical Oncology</i> , 2021, 28, 340-352.	0.7	5
2	BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103128.	2.0	6
3	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	2.3	13
4	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	5.1	41
5	The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study. <i>Cancers</i> , 2021, 13, 5836.	1.7	4
6	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021, 6, 100300.	2.0	9
7	A retrospective analysis on 197 cases of breast cancer local recurrence: Biology, treatment, and prognosis. <i>Breast Journal</i> , 2020, 26, 1096-1098.	0.4	1
8	Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	0.8	69
9	Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. <i>Cancers</i> , 2020, 12, 2239.	1.7	6
10	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. <i>ESMO Open</i> , 2020, 5, e000937.	2.0	10
11	Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal. <i>Breast</i> , 2020, 53, 181-188.	0.9	7
12	ASO Author Reflections: The Difficult Assessment of the Hard-Won Progress of Breast Cancer Care. <i>Annals of Surgical Oncology</i> , 2020, 27, 777-778.	0.7	0
13	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020, 9, 442.	1.8	7
14	Neoadjuvant or adjuvant chemotherapy in early breast cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1071-1082.	0.9	62
15	Is breast conserving therapy better than mastectomy? Surgeons must speak out. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1551-1553.	0.5	2
16	Do all BRCA1/2 carriers with breast cancer benefit from bilateral mastectomy?. <i>Annals of Breast Surgery</i> , 2019, 3, 23-23.	0.8	0
17	Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome. <i>Journal of Clinical Medicine</i> , 2019, 8, 313.	1.0	5
18	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two-centers experience. <i>Journal of Ovarian Research</i> , 2018, 11, 42.	1.3	21

#	ARTICLE	IF	CITATIONS
19	Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers. <i>Clinical Breast Cancer</i> , 2018, 18, e1361-e1366.	1.1	25
20	Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence. <i>Breast</i> , 2018, 41, 8-13.	0.9	2
21	Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 85-95.	1.1	18
22	MRI to predict nipple-areola complex (NAC) involvement: An automatic method to compute the 3D distance between the NAC and tumor. <i>Journal of Surgical Oncology</i> , 2017, 116, 1069-1078.	0.8	8
23	Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. <i>Eancermedalscience</i> , 2016, 10, 639.	0.6	28
24	Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 1-7.	3.4	8
25	Breast Cancer Prevention: Can Women's Expectations Be Met?. <i>Oncologist</i> , 2016, 21, 2-3.	1.9	2
26	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 26181-26191.	0.8	15
27	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. <i>Gynecologic Oncology</i> , 2015, 138, 627-633.	0.6	43
28	MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy. <i>European Journal of Cancer</i> , 2015, 51, 1882-1889.	1.3	63
29	Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. <i>British Journal of Cancer</i> , 2014, 110, 1133-1138.	2.9	10
30	Role of re-excision for positive and close resection margins in patients treated with breast-conserving surgery. <i>Breast</i> , 2014, 23, 870-875.	0.9	24
31	Accelerated partial breast irradiation using 3D conformal radiotherapy: Toxicity and cosmetic outcome. <i>Breast</i> , 2013, 22, 1136-1141.	0.9	5
32	Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 167-174.	1.1	19
33	Loco-regional therapy and breast cancer survival: Searching for a link. <i>Breast</i> , 2013, 22, 510-514.	0.9	6
34	miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. <i>FASEB Journal</i> , 2013, 27, 1223-1235.	0.2	134
35	Does our better understanding of breast cancer also improve the way we treat it?. <i>Gland Surgery</i> , 2013, 2, 1-3.	0.5	16
36	Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 1418-1425.	1.9	79

#	ARTICLE	IF	CITATIONS
37	Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3755-3761.	0.7	20
38	Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. <i>European Journal of Cancer</i> , 2012, 48, 2311-2318.	1.3	55
39	Nipple-areola complex sparing mastectomy with periareolar pexy for breast cancer patients with moderately ptotic breasts. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2012, 65, 296-303.	0.5	33
40	Correlations between diffusion-weighted imaging and breast cancer biomarkers. <i>European Radiology</i> , 2012, 22, 1519-1528.	2.3	206
41	Does immediate reconstruction increase postmastectomy surgical site infection?. <i>Gland Surgery</i> , 2012, 1, 167-8.	0.5	0
42	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 775-784.	1.1	19
43	Variation of Breast Vascular Maps on Dynamic Contrast-Enhanced MRI After Primary Chemotherapy of Locally Advanced Breast Cancer. <i>American Journal of Roentgenology</i> , 2011, 196, 1214-1218.	1.0	19
44	Effects of Surgical and Adjuvant Therapies for Breast Cancer on Sexuality, Cognitive Functions, and Body Weight. <i>Journal of Sexual Medicine</i> , 2010, 7, 1891-1900.	0.3	96
45	Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. <i>Gynecological Endocrinology</i> , 2010, 26, 404-412.	0.7	121
46	Extensive Nodal Disease May Impair Axillary Reverse Mapping in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5547-5551.	0.8	57
47	Decreasing arm morbidity by refining axillary surgery in breast cancer. <i>European Journal of Surgical Oncology</i> , 2009, 35, 335-338.	0.5	3
48	Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. <i>Climacteric</i> , 2009, 12, 310-318.	1.1	49
49	Indications for breast magnetic resonance imaging. Consensus document "Attualità in senologia", Florence 2007. <i>Radiologia Medica</i> , 2008, 113, 1085-1095.	4.7	38
50	Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. <i>International Journal of Cancer</i> , 2008, 123, 1327-1338.	2.3	79
51	Axillary Reverse Mapping in Breast Cancer: Can we Spare what we Find?. <i>Annals of Surgical Oncology</i> , 2008, 15, 390-391.	0.7	43
52	Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers. <i>Maturitas</i> , 2008, 60, 71-77.	1.0	2
53	The Academic Division of Breast and Gynaecological Oncology of the Institute for Cancer Research and Treatment (IRCC) of Candiolo, Turin, Italy. <i>Breast Care</i> , 2008, 3, 287-288.	0.8	0
54	Patients With Breast Cancer Are Unlikely to Benefit From Prophylactic Irradiation of the Contralateral Breast. <i>Journal of Clinical Oncology</i> , 2008, 26, 1014-1015.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Aromatase inhibitors for breast cancer: different structures, same effects?. <i>Endocrine-Related Cancer</i> , 2008, 15, 27-36.	1.6	25
56	Comparison of two models for the prediction of nonsentinel node metastases in breast cancer. <i>American Journal of Surgery</i> , 2007, 193, 686-692.	0.9	66
57	Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes. <i>Maturitas</i> , 2007, 57, 50-55.	1.0	13
58	Mirtazapine for the Treatment of Hot Flushes in Breast Cancer Survivors: A Prospective Pilot Trial. <i>Breast Journal</i> , 2007, 13, 490-495.	0.4	28
59	Pathological classification of ductal carcinoma in situ of the breast correlates with surgical treatment and may be predicted by mammography. <i>Breast</i> , 2007, 16, 495-502.	0.9	4
60	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. <i>European Radiology</i> , 2007, 17, 1490-1497.	2.3	56
61	Personal use of hormone therapy by postmenopausal women doctors and male doctors's wives in Italy after the publication of WHI trial. <i>Maturitas</i> , 2006, 54, 181-192.	1.0	13
62	Antihormones in Prevention and Treatment of Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 143-158.	1.8	24
63	Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1163-1184.	1.2	43
64	Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer. <i>Journal of Chemotherapy</i> , 2006, 18, 90-97.	0.7	5
65	Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Status: An Independent Influence on the Efficacy of Endocrine Therapy in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2006, 24, 1481-1482.	0.8	1
66	Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. <i>Annals of Oncology</i> , 2006, 17, 1631-1636.	0.6	30
67	Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. <i>Maturitas</i> , 2005, 52, 78-85.	1.0	54
68	Vaginal oestrogen therapy after breast cancer: Is it safe?. <i>European Journal of Cancer</i> , 2005, 41, 2673-2681.	1.3	79
69	Management of risk of breast carcinoma in postmenopausal women.. <i>Endocrine-Related Cancer</i> , 2004, 11, 69-83.	1.6	17
70	Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine. <i>Journal of the National Cancer Institute</i> , 2004, 96, 883-884.	3.0	7
71	Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 67-76.	1.1	225
72	Personal use of HRT by postmenopausal women doctors and doctors' wives in the north of Italy. <i>Gynecological Endocrinology</i> , 2004, 18, 165-174.	0.7	15

#	ARTICLE	IF	CITATIONS
73	Hormone replacement therapy in cancer survivors. <i>Maturitas</i> , 2004, 48, 333-346.	1.0	31
74	The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 149-158.	1.1	46
75	Angiotensin-2 expression in breast cancer correlates with lymph node invasion and short survival. <i>International Journal of Cancer</i> , 2003, 103, 466-474.	2.3	182
76	Menopause after breast cancer: a survey on breast cancer survivors. <i>Maturitas</i> , 2003, 45, 29-38.	1.0	225
77	Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens. <i>Maturitas</i> , 2003, 45, 283-291.	1.0	11
78	Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. <i>Radiologia Medica</i> , 2003, 106, 51-8.	4.7	13
79	Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. <i>British Journal of Cancer</i> , 2002, 87, 1287-1293.	2.9	40
80	Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. <i>British Journal of Cancer</i> , 2002, 86, 1457-1464.	2.9	58
81	The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. <i>British Journal of Cancer</i> , 2002, 87, 1294-1300.	2.9	42
82	Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. <i>Clinical Chemistry</i> , 2002, 48, 1241-1250.	1.5	82
83	Beyond randomized controlled trials. <i>Cancer</i> , 2002, 94, 579-580.	2.0	2
84	Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. <i>Clinical Chemistry</i> , 2002, 48, 1241-50.	1.5	33
85	Term breech trial. <i>Lancet</i> , The, 2001, 357, 226-227.	6.3	2
86	The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. <i>British Journal of Cancer</i> , 1999, 79, 311-315.	2.9	43
87	Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. <i>Clinical Biochemistry</i> , 1999, 32, 39-44.	0.8	6
88	Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. <i>Journal of Clinical Laboratory Analysis</i> , 1999, 13, 75-81.	0.9	18
89	HRT, breast and endometrial cancers: strategies and intervention options. <i>Maturitas</i> , 1999, 32, 131-139.	1.0	6
90	Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. , 1998, 79, 147-152.		10

#	ARTICLE	IF	CITATIONS
91	Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. <i>British Journal of Cancer</i> , 1997, 76, 1087-1094.	2.9	50
92	Oral Contraceptive Use and Breast Cancer Risk in Areas with Different Incidence.. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 564-569.	1.8	4
93	Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. <i>British Journal of Cancer</i> , 1996, 73, 386-390.	2.9	42
94	Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 171-178.	1.1	92
95	Prostate-specific antigen in serum of women with breast cancer. <i>British Journal of Cancer</i> , 1995, 72, 728-731.	2.9	54
96	Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test. <i>European Journal of Pediatrics</i> , 1993, 152, 655-661.	1.3	38
97	Hyperphenylalaninemia and pterin metabolism in serum and erythrocytes. <i>Clinica Chimica Acta</i> , 1993, 216, 63-71.	0.5	25
98	Catalytic Activity of Tetrahydrobiopterin in Dihydropteridine Reductase Deficiency and Indications for Treatment. <i>Pediatric Research</i> , 1993, 33, 125-128.	1.1	12
99	Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: The Prevalent Mutation G985 (K304E) Is Subject to a Strong Founder Effect from Northwestern Europe. <i>Human Heredity</i> , 1993, 43, 342-350.	0.4	75
100	Monitoring Treatment in Tetrahydrobiopterin Deficiency. <i>Pteridines</i> , 1991, 3, 13-15.	0.5	6
101	Prenatal Diagnosis of Dihydropteridine Reductase Deficiency in a Twin Pregnancy. <i>Pteridines</i> , 1991, 3, 19-21.	0.5	1
102	RFLPs of the phenylalanine hydroxylase gene in the Italian population. <i>Journal of Inherited Metabolic Disease</i> , 1989, 12, 162-165.	1.7	4